58
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
BIOPHARMACEUTICAL STUDY OF AN ANTIOXIDANT DRUG FORMULATION
BASED ON ST. JOHN’S WORT (HYPERICUM PERFORATUM)
Radjabova D.Q.
1
Ilhamova N.B.
2
Tashkent Pharmaceutical Institute, Tashkent city, Republic of Uzbekistan
e-mail: radjabovadildora36@gmail.com
https://doi.org/10.5281/zenodo.17318368
Introduction.
Oxidative stress plays a key role in the development of many disorders
associated with the cardiovascular and nervous systems as well as chronic inflammation.
Consequently, phytopreparations based on natural antioxidants have been the focus of extensive
pharmaceutical research in recent years. Hypericum perforatum (commonly known as St. John’s
wort) is rich in potent antioxidant constituents such as flavonoids, phenolic compounds, and
chlorogenic acid. Traditionally, this plant has been used in folk medicine for its anti-inflammatory
and sedative effects. Modern pharmaceutical technologies make it possible to develop stable
formulations with high bioavailability from this plant material.
Aim of the Study.
To develop, on a scientific basis, the composition of a medicinal product
derived from Hypericum perforatum extract and to investigate its biopharmaceutical properties.
Materials and Methods.
The research plan includes collecting and standardizing the plant raw
material in accordance with pharmacopeial requirements, selecting optimal extraction methods, and
evaluating excipients such as microcrystalline cellulose, polyvinylpyrrolidone, starch, and others. The
physical-chemical stability of the final dosage form will be tested.
Bioavailability will be assessed using in-vitro dissolution and disintegration tests as well as in-
vivo animal studies. For the dissolution test, according to the XI State Pharmacopeia, in the absence
of specific indicators, the rotating basket apparatus will be operated at 150 rpm for 45 minutes, and
the tablet efficacy must exceed 75 %. For the disintegration test, also following the XI State
Pharmacopeia, in the absence of specific requirements, testing will be performed on six tablets at a
frequency of 28–32 movements per minute for 15 minutes, with a required yield of more than 75 %.
Expected Results.
The study is expected to provide scientifically grounded conclusions
regarding the optimal manufacturing technology of the Hypericum perforatum-based drug, the
influence of excipients, and the parameters of stability and bioavailability. These data will have
practical significance for the development of a new antioxidant phytopreparation.
Conclusion.
A preparation based on Hypericum perforatum extract has the potential to reduce
oxidative stress and may serve as a promising therapeutic agent for the prevention of chronic
inflammation, metabolic syndrome, and cardiovascular diseases.
